Lewis H. Titterton, Jr. Purchases 10,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction dated Friday, January 17th. The stock was acquired at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the acquisition, the director now directly owns 922,334 shares of the company’s stock, valued at $2,370,398.38. The trade was a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Anixa Biosciences Price Performance

ANIX opened at $2.41 on Monday. The company has a market capitalization of $77.55 million, a PE ratio of -6.18 and a beta of 0.90. The business has a fifty day simple moving average of $2.80 and a 200 day simple moving average of $3.03. Anixa Biosciences, Inc. has a 1 year low of $2.07 and a 1 year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. Equities analysts anticipate that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ANIX has been the topic of several recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANIX. International Assets Investment Management LLC increased its holdings in Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the period. Westside Investment Management Inc. lifted its position in shares of Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management boosted its stake in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after buying an additional 21,008 shares in the last quarter. Concorde Asset Management LLC bought a new position in Anixa Biosciences in the second quarter valued at about $31,000. Finally, Virtu Financial LLC acquired a new position in Anixa Biosciences during the third quarter worth about $34,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.